Methods:
Participants with active TB, latent TB and non-tuberculous mycobacterial
(NTM) infection were recruited into the “Assessing Antibiotic-Induced
Liver Injury for the Stratification of Tuberculosis Patients” (ALISTER)
clinical study at the Royal Infirmary, Edinburgh (ClinicalTrials.gov
Identifier: NCT03211208). Participants with HIV-TB coinfection were
recruited into the “Safety and Efficacy of High Dose Rifampicin in
Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or
Dolutegravir-based Antiretroviral Therapy” (SAEFRIF) clinical trial at
the Infectious Disease Institute, Kampala, Uganda (ClinicalTrials.gov
Identifier: NCT03982277).